secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001558370-24-003175
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx reports FY2023 net loss of $84M, down 35% YoY; Janssen deal yields $50M milestone
--------------------------------------------------------------------------------

- Net loss $84.0M ($1.49/share) vs $129.6M ($2.87) in 2022; license revenue $14.0M.
- Janssen asset purchase for bota-vec (XLRP) up to $415M; $65M upfront + $50M milestone in Feb 2024.
- Sanofi invested $30M at $7.50/share; ROFN for riboswitch in CNS, I&I, metabolic disease.
- FDA aligns Phase 2 AQUAx2 for xerostomia as pivotal; AAV-AIPL1 shows meaningful responses in 8 LCA4 children.
- Cash $129.6M at Dec 31, 2023; expects funding into Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837024003175/0001558370-24-003175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837024003175/mgtx-20240314x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-003175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer